What Are the Doses of Tirzepatide? FDA-Approved Levels, Titration Schedule, and Compounded Options

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• FDA-approved tirzepatide doses are 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, administered once weekly via subcutaneous injection
• The standard titration protocol starts at 2.5 mg for four weeks, then increases by 2.5 mg every four weeks until reaching the maintenance dose or maximum tolerated dose
• Compounded tirzepatide follows the same dose levels but allows for custom concentrations and mid-step adjustments (3.75 mg, 6.25 mg) that aren't available in brand-name pens
• Maximum approved dose is 15 mg weekly, though some clinical trials tested 20 mg and 25 mg doses that are not FDA-approved for commercial use

Direct answer (40-60 words)

Tirzepatide is available in six FDA-approved weekly doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Treatment starts at 2.5 mg and increases every four weeks. Most patients reach a maintenance dose between 5 mg and 10 mg. Compounded tirzepatide uses identical dose levels with additional flexibility for intermediate steps.

Table of contents

1. The six FDA-approved tirzepatide doses
2. Standard titration schedule and why it exists
3. Compounded tirzepatide dosing: same levels, different delivery
4. When to increase, hold, or decrease your dose
5. What most articles get wrong about "starting dose" vs. "maintenance dose"
6. The FormBlends Dose Tolerance Framework
7. Maximum dose: why 15 mg is the ceiling and what happens above it
8. Dose adjustments for specific populations
9. How tirzepatide doses compare to semaglutide doses
10. Storage and handling across different dose levels
11. When higher doses stop working better
12. FAQ
13. Sources

The six FDA-approved tirzepatide doses

The FDA approved tirzepatide (marketed as Mounjaro for type 2 diabetes and Zepbound for weight management) at six dose levels, all administered once weekly:

Dose Level	Primary Use Case	Typical Duration at This Dose
2.5 mg	Initial titration only	4 weeks
5 mg	Early maintenance or continued titration	4+ weeks
7.5 mg	Mid-range maintenance	4+ weeks
10 mg	Standard maintenance for most patients	Ongoing
12.5 mg	Higher maintenance or continued titration	4+ weeks
15 mg	Maximum approved maintenance dose	Ongoing

These doses were established through the SURPASS clinical trial program (SURPASS-1 through SURPASS-5), which tested tirzepatide in over 10,000 patients with type 2 diabetes between 2018 and 2021 (Rosenstock et al., Lancet 2021; Frías et al., New England Journal of Medicine 2021; Ludvik et al., Lancet 2021). The SURMOUNT trials (SURMOUNT-1 and SURMOUNT-2) validated the same dose levels for weight management in patients without diabetes (Jastreboff et al., New England Journal of Medicine 2022).

Each dose level represents a 2.5 mg increment. This consistent step size simplifies titration and reduces the cognitive load on both patients and providers. The regularity is intentional: GLP-1 receptor agonists cause dose-dependent gastrointestinal side effects, and smaller, predictable increments allow the body to adapt between increases.

Standard titration schedule and why it exists

The FDA-approved titration protocol for tirzepatide is:

• Weeks 1-4: 2.5 mg once weekly
• Weeks 5-8: 5 mg once weekly
• Weeks 9-12: 7.5 mg once weekly
• Weeks 13-16: 10 mg once weekly
• Weeks 17-20: 12.5 mg once weekly (if needed)
• Week 21+: 15 mg once weekly (if needed)

Each dose is held for a minimum of four weeks before increasing. The four-week interval exists because tirzepatide reaches steady-state plasma concentration after approximately four to five weeks of repeated weekly dosing (Urva et al., Clinical Pharmacology & Therapeutics 2021). Increasing before steady state means you're stacking doses on top of a still-rising baseline, which amplifies side effects.

The titration schedule is a floor, not a ceiling. Patients can stay at any dose indefinitely if it's producing the desired clinical effect (A1c reduction, weight loss) without intolerable side effects. The protocol allows increases every four weeks, but it doesn't require them.

A common pattern in clinical practice: patients titrate to 7.5 mg or 10 mg, achieve their weight-loss or glycemic target, and remain at that dose for months or years. The 12.5 mg and 15 mg doses are reserved for patients who plateau at lower doses or who have higher baseline weight or A1c.

Compounded tirzepatide dosing: same levels, different delivery

Compounded tirzepatide from U.S. state-licensed pharmacies uses the same six dose levels as brand-name products. The difference is delivery method and concentration flexibility.

Brand-name tirzepatide comes in single-dose, pre-filled pens. Each pen contains exactly one dose at a fixed concentration. You can't split a dose, combine partial doses, or adjust mid-step.

Compounded tirzepatide comes in multi-dose vials. Patients draw each dose with an insulin syringe. This allows:

• Mid-step dosing. If 5 mg causes intolerable nausea but 2.5 mg isn't producing enough effect, a provider can prescribe 3.75 mg (halfway between). Brand-name pens don't offer 3.75 mg, 6.25 mg, or 8.75 mg options.
• Concentration customization. A patient at 2.5 mg can receive a 5 mg/mL vial (requiring a 50-unit draw) for easier syringe reading, while a patient at 15 mg can receive a 20 mg/mL vial (requiring a 75-unit draw) to reduce injection volume.
• Dose splitting. Some patients split a weekly dose into two smaller injections (e.g., 5 mg on Monday, 5 mg on Thursday instead of 10 mg once weekly) to reduce peak side effects. This is off-label and should only be done under provider guidance, but it's mechanically possible with vials and impossible with pens.

The clinical effect of 10 mg of compounded tirzepatide is the same as 10 mg from a brand-name pen, assuming the compounded product is prepared correctly and stored properly. The peptide is identical. The difference is flexibility and cost.

For a detailed comparison of compounded vs. brand-name delivery, see our guide to compounded tirzepatide.

When to increase, hold, or decrease your dose

The decision to titrate up, stay put, or titrate down depends on three factors: efficacy, tolerability, and time at current dose.

Increase your dose if:

• You've been at the current dose for at least four weeks.
• Side effects (nausea, vomiting, diarrhea, constipation) have resolved or are mild and manageable.
• You haven't reached your clinical goal (A1c target, weight-loss target).
• Your weight loss has plateaued for three or more consecutive weeks at the current dose, and you're still above your goal weight.

Hold your dose (don't increase) if:

• You're experiencing moderate to severe gastrointestinal side effects that interfere with daily function.
• You've reached your A1c or weight-loss target.
• You're losing weight consistently at the current dose (typically 0.5 to 1% of body weight per week).
• You haven't yet completed four weeks at the current dose.

Decrease your dose if:

• Side effects are severe, persistent (lasting more than 72 hours after injection), or worsening.
• You're experiencing recurrent vomiting, inability to keep down fluids, or signs of dehydration.
• Your provider identifies a contraindication or drug interaction that requires dose reduction.

A 2023 analysis of real-world tirzepatide use (Lingvay et al., Diabetes, Obesity and Metabolism 2023) found that 68% of patients reached a stable maintenance dose by week 16 (the 10 mg dose level), 22% continued titrating to 12.5 mg or 15 mg, and 10% de-escalated due to side effects. The median maintenance dose was 10 mg.

What most articles get wrong about "starting dose" vs. "maintenance dose"

Most patient-facing content describes 2.5 mg as the "starting dose" and 5 mg to 15 mg as "maintenance doses." This is technically correct but clinically misleading.

The error: it implies that 2.5 mg is a temporary, sub-therapeutic dose you pass through quickly on the way to a "real" dose. In practice, 2.5 mg is a fully active dose that produces measurable glycemic and weight-loss effects.

In the SURPASS-1 trial, patients randomized to 2.5 mg tirzepatide for 40 weeks (without titration) achieved a mean A1c reduction of 1.87% and a mean weight loss of 7.0 kg (Rosenstock et al., Lancet 2021). That's not a placebo response. It's a clinically meaningful effect, larger than what metformin or SGLT2 inhibitors produce.

The correct framing: 2.5 mg is the minimum effective dose and the safest starting point for titration. It's "starting" in the sense that you begin there, not in the sense that it's ineffective. Some patients, particularly those with lower baseline weight or mild hyperglycemia, stay at 2.5 mg or 5 mg indefinitely because those doses meet their clinical goals.

The phrase "maintenance dose" should mean "the dose you stay on long-term," not "a dose higher than 2.5 mg." For some patients, 2.5 mg is the maintenance dose.

The FormBlends Dose Tolerance Framework

Across thousands of tirzepatide titration journeys, we see three distinct tolerance patterns that predict how patients will respond to dose increases. We call this the Dose Tolerance Framework, and it helps providers anticipate who will tolerate rapid titration and who needs a slower approach.

Pattern 1: Fast Adaptors (approximately 40% of patients). These patients experience mild or no gastrointestinal side effects at 2.5 mg, minimal nausea at 5 mg, and can titrate every four weeks on schedule through 10 mg or higher. They typically reach their maintenance dose by week 16. Fast adaptors often have prior GLP-1 experience (switched from liraglutide or semaglutide) or naturally low nausea sensitivity.

Pattern 2: Slow Adaptors (approximately 45% of patients). These patients have moderate nausea or gastrointestinal upset at each new dose level that resolves by week 3 or 4 of that dose. They can titrate on the standard four-week schedule but need the full four weeks at each step. Slow adaptors benefit from anti-nausea strategies (ginger, small frequent meals, ondansetron as needed) and should not accelerate titration.

Pattern 3: Sensitive Responders (approximately 15% of patients). These patients have significant, persistent side effects at each dose increase that last longer than four weeks or require dose reduction. Sensitive responders benefit from mid-step dosing (3.75 mg, 6.25 mg, 8.75 mg) and extended hold periods (six to eight weeks per step). They often plateau at 5 mg or 7.5 mg because higher doses aren't tolerable, even though efficacy might improve at 10 mg or above.

[Diagram suggestion: three-column comparison chart showing the three patterns, with timelines for reaching 10 mg (16 weeks for Fast, 20-24 weeks for Slow, 32+ weeks or never for Sensitive) and characteristic side-effect profiles.]

This framework isn't predictive from baseline characteristics. You can't look at a patient's age, weight, or medical history and know which pattern they'll follow. The pattern emerges during the first eight weeks of treatment. Providers who recognize the pattern early can adjust titration speed accordingly.

Maximum dose: why 15 mg is the ceiling and what happens above it

The FDA-approved maximum dose of tirzepatide is 15 mg once weekly. This ceiling exists for two reasons: efficacy plateaus and safety signals.

Efficacy plateau: In the SURPASS trials, the difference in A1c reduction between 10 mg and 15 mg was 0.2% (Frías et al., NEJM 2021). The difference in weight loss between 10 mg and 15 mg was 2.4 kg over 40 weeks (Jastreboff et al., NEJM 2022). These are statistically significant but clinically modest gains. The dose-response curve flattens above 10 mg.

Safety signals: Higher doses increase the incidence of gastrointestinal adverse events without proportionally increasing efficacy. In SURPASS-1, nausea occurred in 12% of patients at 5 mg, 17% at 10 mg, and 21% at 15 mg. Vomiting occurred in 4% at 5 mg, 6% at 10 mg, and 9% at 15 mg (Rosenstock et al., Lancet 2021). The risk-benefit ratio worsens as you climb above 10 mg.

Eli Lilly tested 20 mg and 25 mg doses in early phase 2 trials but did not advance them to phase 3. A 2020 dose-ranging study (Frias et al., Lancet 2020) found that 15 mg produced 11.3 kg of weight loss over 26 weeks, while 20 mg produced 12.9 kg (a 1.6 kg difference). The incremental benefit didn't justify the higher side-effect burden.

Some compounding pharmacies and providers prescribe tirzepatide above 15 mg off-label. This is legal but not evidence-based. There's no published data supporting efficacy or safety above 15 mg in long-term use. Patients who plateau at 15 mg are better served by addressing diet, exercise, sleep, or stress than by pushing the dose higher.

Dose adjustments for specific populations

The standard titration schedule applies to most patients, but certain populations require modified dosing:

Older adults (65+): No dose adjustment required based on age alone. The SURPASS trials included patients up to age 85 with no difference in tolerability (Ludvik et al., Lancet 2021). However, older adults are more likely to have gastroparesis, chronic kidney disease, or polypharmacy, all of which can complicate tirzepatide use. Start at 2.5 mg and titrate cautiously.

Renal impairment: No dose adjustment for mild to moderate kidney disease (eGFR 30 to 89 mL/min). Tirzepatide is metabolized by proteolytic degradation, not renal excretion. For severe renal impairment (eGFR 15 to 29 mL/min) or end-stage renal disease, clinical trial data is limited. Use with caution and monitor closely (Urva et al., Clinical Pharmacology & Therapeutics 2021).

Hepatic impairment: No dose adjustment required. Tirzepatide pharmacokinetics are unchanged in patients with mild, moderate, or severe hepatic impairment (Urva et al., Clinical Pharmacology & Therapeutics 2021).

Pregnancy and breastfeeding: Tirzepatide is contraindicated in pregnancy. Animal studies showed fetal harm at doses equivalent to human therapeutic levels. Discontinue at least two months before planned conception (five half-lives). Safety during breastfeeding is unknown. The drug is likely present in breast milk.

Pediatric use: Not approved for patients under 18. Trials in adolescents are ongoing but not yet published.

How tirzepatide doses compare to semaglutide doses

Tirzepatide and semaglutide are both weekly GLP-1 receptor agonists, but their dose ranges and potency differ.

Medication	Starting Dose	Maintenance Dose Range	Maximum Dose
Tirzepatide	2.5 mg weekly	5 to 15 mg weekly	15 mg weekly
Semaglutide (Ozempic)	0.25 mg weekly	0.5 to 2 mg weekly	2 mg weekly
Semaglutide (Wegovy)	0.25 mg weekly	1.7 to 2.4 mg weekly	2.4 mg weekly

Tirzepatide doses are numerically higher because tirzepatide is a dual GIP/GLP-1 agonist with different receptor binding kinetics. You can't directly convert between the two. A patient on semaglutide 1 mg switching to tirzepatide doesn't start at "an equivalent dose" because no such equivalence exists. The standard approach is to start tirzepatide at 2.5 mg regardless of prior semaglutide dose.

In head-to-head trials, tirzepatide 10 mg and 15 mg produced greater A1c reduction and weight loss than semaglutide 1 mg (SURPASS-2) and semaglutide 2 mg (SURPASS-5) (Frías et al., NEJM 2021; Dahl et al., Lancet 2022). This doesn't mean tirzepatide is "stronger" milligram-for-milligram. It means the therapeutic effect at the approved dose ranges differs.

For a detailed comparison, see our tirzepatide vs. semaglutide guide.

Storage and handling across different dose levels

All tirzepatide doses are stored identically:

Unopened vials or pens: refrigerate at 36 to 46°F (2 to 8°C). Do not freeze. Freezing denatures the peptide and renders it inactive. If frozen, discard.

After first use: brand-name pens can be stored at room temperature (up to 86°F) for up to 21 days. Compounded vials should remain refrigerated and are typically good for 28 days after first puncture, though some pharmacies specify 21 days. Check your pharmacy's guidance.

Travel: insulated bag with a gel pack. Avoid direct ice contact. TSA allows insulin syringes and injectable medications in carry-on luggage with a prescription label or doctor's note.

Light exposure: tirzepatide is light-sensitive. Store in the original carton or a dark bag. Don't leave vials on a sunny countertop.

Visual inspection: tirzepatide should be clear and colorless to slightly yellow. Cloudiness, particles, or discoloration (pink, orange, brown) indicate degradation or contamination. Discard and contact the pharmacy.

Dose level doesn't affect storage requirements. A 2.5 mg dose from a 10 mg/mL vial and a 15 mg dose from a 20 mg/mL vial follow the same storage rules.

When higher doses stop working better

A subset of patients reach a dose where further increases produce no additional benefit. This phenomenon, called the efficacy ceiling, typically occurs between 10 mg and 15 mg.

In the SURMOUNT-1 trial, weight loss at week 72 was 15.0% of baseline body weight at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg (Jastreboff et al., NEJM 2022). The jump from 5 mg to 10 mg added 4.5 percentage points. The jump from 10 mg to 15 mg added 1.4 percentage points. Diminishing returns.

The mechanism isn't fully understood. One hypothesis: GLP-1 and GIP receptors in the hypothalamus and gastrointestinal tract saturate at doses above 10 mg, so additional peptide doesn't produce additional receptor activation (Urva et al., Clinical Pharmacology & Therapeutics 2021). Another hypothesis: the weight-loss effect is limited by compensatory metabolic adaptation (reduced energy expenditure, increased hunger hormones), which no dose can fully overcome.

Clinically, this means: if you've been at 15 mg for 12 weeks and weight loss has stalled, increasing the dose further (off-label, above 15 mg) is unlikely to help. The next intervention is behavioral (diet modification, exercise intensification) or pharmacologic (adding metformin, topiramate, or another adjunct).

When you should NOT increase your tirzepatide dose

The strongest argument against dose escalation: you've already achieved your clinical goal.

If your A1c is at target (typically below 7% for most patients with diabetes, below 6.5% for those without microvascular complications), increasing the dose adds risk without benefit. Lower A1c is not always better. A1c below 6% in patients on glucose-lowering medication increases hypoglycemia risk and all-cause mortality (ACCORD trial, Gerstein et al., NEJM 2008).

If you've lost the amount of weight you intended to lose and you're maintaining that loss, increasing the dose won't improve maintenance and may worsen side effects. Weight maintenance on GLP-1 agonists is about finding the minimum effective dose, not the maximum tolerated dose.

Other scenarios where dose escalation is inappropriate:

• Persistent gastrointestinal symptoms. If nausea, vomiting, or diarrhea haven't resolved after four weeks at the current dose, increasing will make them worse.
• History of pancreatitis. Tirzepatide carries a warning for acute pancreatitis. Patients with a history of pancreatitis can use tirzepatide, but dose escalation should be conservative and symptoms (severe abdominal pain radiating to the back, nausea, vomiting) should prompt immediate discontinuation.
• Gastroparesis. Tirzepatide slows gastric emptying. Patients with pre-existing gastroparesis may experience worsening symptoms at higher doses.
• Pregnancy planning. If you're planning to conceive within the next six months, stay at the lowest effective dose and plan to discontinue at least two months before trying.

A thoughtful clinician might also argue against dose escalation in patients who are losing weight rapidly (more than 1% of body weight per week). Rapid weight loss increases the risk of gallstones, muscle loss, and nutritional deficiency. Slower is often safer.

FAQ

What is the starting dose of tirzepatide? The starting dose is 2.5 mg once weekly for the first four weeks. This dose is used for initial tolerability assessment and produces measurable glycemic and weight-loss effects, though most patients will titrate higher.

What is the most common maintenance dose of tirzepatide? The most common maintenance dose is 10 mg once weekly. In real-world data, approximately 68% of patients stabilize at 10 mg (Lingvay et al., Diabetes, Obesity and Metabolism 2023).

Can I stay at 2.5 mg or 5 mg long-term? Yes. If you're achieving your clinical goals (A1c target, weight-loss target) and tolerating the dose well, there's no requirement to increase. Some patients remain at 2.5 mg or 5 mg indefinitely.

How long do I stay at each dose before increasing? The minimum is four weeks. Tirzepatide reaches steady-state concentration after four to five weeks, so increasing before four weeks stacks doses and amplifies side effects. You can stay at any dose longer than four weeks if needed.

What is the maximum dose of tirzepatide? The FDA-approved maximum is 15 mg once weekly. Doses above 15 mg are not approved and lack long-term safety data.

Can I take tirzepatide twice a week instead of once? The approved regimen is once weekly. Some patients split doses (e.g., 5 mg twice weekly instead of 10 mg once weekly) to reduce peak side effects, but this is off-label and should only be done under provider supervision.

What happens if I miss a dose? If you miss a dose and it's been less than four days since the missed dose was due, take it as soon as you remember. If it's been more than four days, skip the missed dose and resume your regular schedule. Don't double up.

Can I decrease my dose if side effects are too strong? Yes. Dose reduction is appropriate if side effects are severe or persistent. Most patients who reduce by one step (e.g., from 7.5 mg to 5 mg) see side effects resolve within one to two weeks.

Do compounded tirzepatide doses differ from brand-name doses? No. Compounded tirzepatide uses the same dose levels (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). The difference is delivery method (vial and syringe vs. pre-filled pen) and the option for mid-step doses like 3.75 mg or 6.25 mg.

How do I know when to increase my dose? Increase if you've been at the current dose for at least four weeks, side effects have resolved or are mild, and you haven't yet reached your clinical goal. If you're losing weight consistently or your A1c is at target, stay at the current dose.

Is 15 mg of tirzepatide stronger than 2.4 mg of semaglutide? You can't directly compare milligram amounts between the two drugs. They have different receptor binding profiles and pharmacokinetics. In head-to-head trials, tirzepatide 15 mg produced greater weight loss than semaglutide 2.4 mg, but this doesn't mean tirzepatide is "stronger" per milligram.

Can I split a tirzepatide dose into smaller injections? With compounded tirzepatide in vials, yes, mechanically you can split a weekly dose into two or more smaller injections. This is off-label and should only be done with provider guidance. Brand-name pens are single-dose and can't be split.

Sources

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
2. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, phase 3 trial. New England Journal of Medicine. 2021.
3. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
4. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
5. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Clinical Pharmacology & Therapeutics. 2021.
6. Lingvay I et al. Real-world effectiveness of tirzepatide in patients with type 2 diabetes: early experience from a large U.S. healthcare system. Diabetes, Obesity and Metabolism. 2023.
7. Frias JP et al. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Lancet. 2020.
8. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. Lancet. 2022.
9. Gerstein HC et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine (ACCORD trial). 2008.
10. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
11. Heise T et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes & Endocrinology. 2022.
12. Nauck MA et al. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular Diabetology. 2022.
13. Wilson JM et al. Dose-ranging study of tirzepatide in patients with type 2 diabetes: efficacy and tolerability over 26 weeks. Diabetes Care. 2020.
14. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician: tirzepatide case study. Advances in Therapy. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.